143 related articles for article (PubMed ID: 22939006)
21. One milligram of lorazepam does not decrease anxiety induced by CCK-4 in healthy volunteers: investigation of neural correlates with BOLD MRI.
Schunck T; Mathis A; Erb G; Namer IJ; Hode Y; Demazières A; Luthringer R
J Psychopharmacol; 2011 Jan; 25(1):52-9. PubMed ID: 20498136
[TBL] [Abstract][Full Text] [Related]
22. Symptom-network dynamics in irritable bowel syndrome with comorbid panic disorder using electronic momentary assessment: A randomized controlled trial of escitalopram vs. placebo.
Kreiter D; Drukker M; Mujagic Z; Vork L; Rutten BPF; van Os J; Masclee AAM; Kruimel JW; Leue C
J Psychosom Res; 2021 Feb; 141():110351. PubMed ID: 33412422
[TBL] [Abstract][Full Text] [Related]
23. Megestrol attenuates the hormonal response to CCK-4-induced panic attacks.
Raedler TJ; Jahn H; Goedeken B; Gescher DM; Kellner M; Wiedemann K
Depress Anxiety; 2006; 23(3):139-44. PubMed ID: 16470820
[TBL] [Abstract][Full Text] [Related]
24. Effect of BI 1358894 on Cholecystokinin-Tetrapeptide (CCK-4)-Induced Anxiety, Panic Symptoms, and Stress Biomarkers: A Phase I Randomized Trial in Healthy Males.
Goettel M; Fuertig R; Mack SR; Just S; Sharma V; Wunder A; den Boer J
CNS Drugs; 2023 Dec; 37(12):1099-1109. PubMed ID: 38019356
[TBL] [Abstract][Full Text] [Related]
25. Paroxetine : a review of its pharmacology and therapeutic potential in the management of panic disorder.
Foster RH; Goa KL
CNS Drugs; 1997 Aug; 8(2):163-88. PubMed ID: 23338224
[TBL] [Abstract][Full Text] [Related]
26. Impact of 5-HTTLPR on SSRI serotonin transporter blockade during emotion regulation: A preliminary fMRI study.
Outhred T; Das P; Dobson-Stone C; Felmingham KL; Bryant RA; Nathan PJ; Malhi GS; Kemp AH
J Affect Disord; 2016 May; 196():11-9. PubMed ID: 26896742
[TBL] [Abstract][Full Text] [Related]
27. Functional neuroanatomy of CCK-4-induced panic attacks in healthy volunteers.
Eser D; Leicht G; Lutz J; Wenninger S; Kirsch V; Schüle C; Karch S; Baghai T; Pogarell O; Born C; Rupprecht R; Mulert C
Hum Brain Mapp; 2009 Feb; 30(2):511-22. PubMed ID: 18095276
[TBL] [Abstract][Full Text] [Related]
28. Vigabatrin decreases cholecystokinin-tetrapeptide (CCK-4) induced panic in healthy volunteers.
Zwanzger P; Baghai TC; Schuele C; Ströhle A; Padberg F; Kathmann N; Schwarz M; Möller HJ; Rupprecht R
Neuropsychopharmacology; 2001 Nov; 25(5):699-703. PubMed ID: 11682253
[TBL] [Abstract][Full Text] [Related]
29. Enhanced sensitivity to cholecystokinin tetrapeptide in panic disorder. Clinical and behavioral findings.
Bradwejn J; Koszycki D; Shriqui C
Arch Gen Psychiatry; 1991 Jul; 48(7):603-10. PubMed ID: 2069490
[TBL] [Abstract][Full Text] [Related]
30. Anxiolytic activity of atrial natriuretic peptide in patients with panic disorder.
Ströhle A; Kellner M; Holsboer F; Wiedemann K
Am J Psychiatry; 2001 Sep; 158(9):1514-6. PubMed ID: 11532742
[TBL] [Abstract][Full Text] [Related]
31. Differential effects to CCK-4-induced panic by dexamethasone and hydrocortisone.
Demiralay C; Jahn H; Kellner M; Yassouridis A; Wiedemann K
World J Biol Psychiatry; 2012 Oct; 13(7):526-34. PubMed ID: 22111662
[TBL] [Abstract][Full Text] [Related]
32. Dose ranging study of the effects of cholecystokinin in healthy volunteers.
Bradwejn J; Koszycki D; Bourin M
J Psychiatry Neurosci; 1991 Jul; 16(2):91-5. PubMed ID: 1911739
[TBL] [Abstract][Full Text] [Related]
33. The cholecystokinin-B receptor antagonist CI-988 failed to affect CCK-4 induced symptoms in panic disorder patients.
van Megen HJ; Westenberg HG; den Boer JA; Slaap B; van Es-Radhakishun F; Pande AC
Psychopharmacology (Berl); 1997 Feb; 129(3):243-8. PubMed ID: 9084062
[TBL] [Abstract][Full Text] [Related]
34. The ventilatory response to cholecystokinin tetrapeptide in healthy volunteers.
Katzman MA; Duffin J; Shlik J; Bradwejn J
Neuropsychopharmacology; 2002 Jun; 26(6):824-31. PubMed ID: 12007753
[TBL] [Abstract][Full Text] [Related]
35. The 5-HTTLPR genotype modulates heart rate variability and its adjustment by pharmacological panic challenge in healthy men.
Agorastos A; Kellner M; Stiedl O; Muhtz C; Becktepe JS; Wiedemann K; Demiralay C
J Psychiatr Res; 2014 Mar; 50():51-8. PubMed ID: 24342768
[TBL] [Abstract][Full Text] [Related]
36. The effect of cholecystokinin tetrapeptide on respiratory resistance in healthy volunteers.
Shlik J; Vasar V; Aluoja A; Kingisepp PH; Jagomägi K; Vasar E; Rägo L; Bradwejn J
Biol Psychiatry; 1997 Aug; 42(3):206-12. PubMed ID: 9232213
[TBL] [Abstract][Full Text] [Related]
37. Effect of oral ondansetron on total cholecystokinin plasma levels following CCK-4 panic challenge procedure in healthy men.
Dépôt M; Merani S; Bradwejn J; Mukherjee J; Caillé J; Gutkowska J; Caillé G
J Psychiatry Neurosci; 1998 Nov; 23(5):298-304. PubMed ID: 9846035
[TBL] [Abstract][Full Text] [Related]
38. Effect of aging on cholecystokinin-induced panic.
Flint AJ; Koszycki D; Vaccarino FJ; Cadieux A; Boulenger JP; Bradwejn J
Am J Psychiatry; 1998 Feb; 155(2):283-5. PubMed ID: 9464213
[TBL] [Abstract][Full Text] [Related]
39. Escitalopram : a review of its use in the management of major depressive and anxiety disorders.
Waugh J; Goa KL
CNS Drugs; 2003; 17(5):343-62. PubMed ID: 12665392
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of the CCK-4 model as a challenge paradigm in a population of healthy volunteers within a proof-of-concept study.
Eser D; Schüle C; Baghai T; Floesser A; Krebs-Brown A; Enunwa M; de la Motte S; Engel R; Kucher K; Rupprecht R
Psychopharmacology (Berl); 2007 Jul; 192(4):479-87. PubMed ID: 17318504
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
